Polsinelli’s multi-disciplinary Life Sciences practice provides the entire spectrum of legal needs to clients in the rapidly growing life sciences industries. Ranging from mature businesses to entrepreneurs to research organizations and scientists, our attorneys deliver tailored and focused representation, coordinating our clients’ needs in the areas of intellectual property and technology transfer, FDA and health care regulatory, corporate finance, real estate development, and nonprofit organizations, among others. Our clients cover the entire field of the life sciences industry, including those involved with: 
  • Drug development
  • Medical devices 
  • Diagnostics
  • Generic drugs
  • Pharmacies and compounding pharmacies 
  • Animal health 
  • Plant science 
  • Biosecurity
We take leading roles on issues affecting the industry, including economic development and legislative initiatives. By working closely with industry leaders in research, politics and business, we are able to provide clients with knowledgeable counsel, industry insight, and key contacts. Utilizing our national experience and broad contacts in the life sciences industry, we are able to assist our clients by providing advice grounded in real industry experience.

Examples of our recent life sciences experience include developing and implementing comprehensive intellectual property portfolios, executing M&A sales and strategic transactions for mature private equity portfolio companies, and venture capital including angel investments for human health spinouts. Additionally, members of our practice serve as special intellectual property and FDA and health care regulatory counsel for publicly traded companies in the areas of animal health and human diagnostics. The Life Sciences practice brings together legal leaders from the following disciplines to help our clients achieve their business and financial goals on a strategic and fully integrated basis:
  • Sale of CyDex Pharmaceuticals, Inc. to Ligand Pharmaceuticals Incorporated 
  • Sale of Planet Biopharmaceuticals, Inc. to Ares Allergy Holdings Inc.
  • Sale of Cedarburg Pharmaceuticals, Inc. to Albany Molecular Research, Inc. ($40+ million)
  • Represented an emerging anti-cancer company in a collaboration and license agreement with a major industry player followed by a restructure and sale of its assets
  • Represented an emerging company developing novel COX-2 inhibitors for the treatment of cancer in a collaboration and license agreement with an international health institute

  • Purchase by the U.S. bioscience joint venture between two multinational technology companies, of a controlling interest in a pandemic influenza manufacturing company from its university and state governmental founders

Medical Device
  • Represented Novita Therapeutics LLC in spinout and add-on venture financing of two medical device technologies into new medical device ventures, Metactive Medical, Inc. and Flow Forward Medical, Inc. 
  • Sale of stock of medical device company Enturia Holding, Inc. to Cardinal Health, Inc. 
  • Negotiated recapitalization transaction and venture capital financing transaction for medical device company in the prenatal NICU equipment space
  • Representation of a publicly traded micro-surgical instrument medical device company in establishing a strategic joint development agreement with a major national medical clinic
  • Multiple venture capital financings by Open Prairie Ventures and the Kansas BioScience Authority in Novita Therapeutics LLC

Compounding Pharmacy
  • Sale of a major US compounding pharmacy to a leading
    European-based international compounding pharmacy conglomerate

  • Sale of assets of Oncimmune (USA), LLC to Health Diagnostic Laboratory, Inc.
  • Represented a national diagnostics company in structuring and documenting multiple-site clinical trials on new diagnostic testing protocol with Mayo Clinic, Laureate Institute for Brain Research, Inc., The McLean Hospital Corporation and the University of Minnesota
  • Represented Beyond Battens Disease Foundation in negotiation of license for broad screening test for orphan pediatric diseases
  • Served as Special IP and regulatory counsel to a national diagnostics company in initial public securities offerings and follow-on offerings

Animal Health/Agriculture
  • Represented founders in formation and funding of TechAccel LLC, the first private capital, co-development partner focused on the acquisition and advancement of technologies in partnership with leading global companies in agriculture, animal health and food sectors
  • Served as special IP and regulatory counsel to Aratana Therapeutics, an animal-health biotech company, in initial public securities offering and follow-on offerings
  • Corporate restructuring, technology in-licensing transactions, and venture capital funding for Centaur Animal Health
  • Represented Australia’s leading animal health company in navigating U.S. regulatory hurdles, establishing a sales and distribution network and to enter the United States market
  • Represented a consortium of animal health manufacturers and distributors in transferring assets to, and acquiring new technology lines for, a new manufacturing and distribution system
  • Negotiated strategic partnerships and research and development agreements for TechAccel with Kansas State University
  • Structured angel investor funding and state tax credit program for initial investors in Aratana Therapeutics
  • Represented the interests of Kansas City Area Life Sciences Institute and other of the world’s leading animal health companies in establishing the Center of Animal Health Innovation to help accelerate the development of early stage animal health technologies

Plant Science
  • Sale of a leading ag-bio control company to Monsanto Company
  • Represented an emerging ag-bio company in a multi-million dollar collaborative research and license agreement with a major crop sciences company

  • Represented Kansas State University in matters relating to obtaining federal funding from the Department of Homeland Security for the construction of the $1.2 billion National Bio and Agro-Defense Facility, the nation’s newest federal laboratory located in Manhattan, Kansas

Related News